Search research articles
Contact Us
Filters
Showing results (51-60 of 188) with videos related to
Page
of 19
Sort By:
Journal of Neurochemistry
|
May 30, 2007
Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation
Francesca Novi, Mark J Millan, Giovanni U Corsini, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
May 14, 2014
Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment
Mark J Millan, Kevin Fone, Thomas Steckler, et al.
Psychopharmacology
|
October 19, 2006
Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors
Mark J Millan, Loretta Iob, Jean-Louis Péglion, et al.
Psychopharmacology
|
July 12, 2002
Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors
Didier Cussac, Delphine Duqueyroix, Adrian Newman-Tancredi, et al.
Molecular Pharmacology
|
August 16, 2002
Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT(1A) receptor-mediated Galpha(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling
Adrian Newman-Tancredi, Didier Cussac, Laetitia Marini, et al.
The International Journal of Neuropsychopharmacology
|
May 8, 2014
CRF₂ receptor-deficiency reduces recognition memory deficits and vulnerability to stress induced by cocaine withdrawal
Nadège Morisot, Catherine Le Moine, Mark J Millan, et al.
Experimental Neurology
|
October 12, 2004
Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells
Steve P Presgraves, Sabine Borwege, Mark J Millan, et al.
Journal of Neurochemistry
|
September 11, 2012
Pharmacological or genetic blockade of the dopamine D3 receptor increases cell proliferation in the hippocampus of adult mice
Martin Egeland, Xiaoqun Zhang, Mark J Millan, et al.
Parkinsonism & Related Disorders
|
February 4, 2010
Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance
Roberto Maggio, Gabriella Aloisi, Elena Silvano, et al.
Trends in Pharmacological Sciences
|
August 5, 2008
Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions
Mark J Millan, Philippe Marin, Joëel Bockaert, et al.
Page
of 19
Search research articles
Search
Showing results (51-60 of 188) with videos related to
Sort By:
Page
of 19
Journal of Neurochemistry
|
May 30, 2007
Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation
Francesca Novi, Mark J Millan, Giovanni U Corsini, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
May 14, 2014
Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment
Mark J Millan, Kevin Fone, Thomas Steckler, et al.
Psychopharmacology
|
October 19, 2006
Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors
Mark J Millan, Loretta Iob, Jean-Louis Péglion, et al.
Psychopharmacology
|
July 12, 2002
Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors
Didier Cussac, Delphine Duqueyroix, Adrian Newman-Tancredi, et al.
Molecular Pharmacology
|
August 16, 2002
Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT(1A) receptor-mediated Galpha(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling
Adrian Newman-Tancredi, Didier Cussac, Laetitia Marini, et al.
The International Journal of Neuropsychopharmacology
|
May 8, 2014
CRF₂ receptor-deficiency reduces recognition memory deficits and vulnerability to stress induced by cocaine withdrawal
Nadège Morisot, Catherine Le Moine, Mark J Millan, et al.
Experimental Neurology
|
October 12, 2004
Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells
Steve P Presgraves, Sabine Borwege, Mark J Millan, et al.
Journal of Neurochemistry
|
September 11, 2012
Pharmacological or genetic blockade of the dopamine D3 receptor increases cell proliferation in the hippocampus of adult mice
Martin Egeland, Xiaoqun Zhang, Mark J Millan, et al.
Parkinsonism & Related Disorders
|
February 4, 2010
Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance
Roberto Maggio, Gabriella Aloisi, Elena Silvano, et al.
Trends in Pharmacological Sciences
|
August 5, 2008
Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions
Mark J Millan, Philippe Marin, Joëel Bockaert, et al.
Page
of 19